iRhythm/$IRTC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About iRhythm

iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Ticker

$IRTC
Sector
Primary listing

Employees

2,000

iRhythm Metrics

BasicAdvanced
$5.5B
-
-$2.93
1.41
-

What the Analysts think about iRhythm

Analyst ratings (Buy, Hold, Sell) for iRhythm stock.

Bulls say / Bears say

Q2 2025 revenue rose 26.1% year-over-year to $186.7 million, fueled by strong demand across core long-term monitoring, rising Zio AT adoption, and international market strength (GlobeNewswire)
Gross margin increased to 71.2% in Q2 2025, up 130 basis points from the previous year, indicating favorable volume leverage and operational efficiency improvements despite a higher-cost product mix (GlobeNewswire)
Established a strategic AI partnership with Lucem Health in Q2 2025 to advance early arrhythmia detection in high-risk groups, strengthening predictive care capabilities (GlobeNewswire)
Net loss remained at $14.2 million (–$0.44 per share) in Q2 2025 despite revenue growth, highlighting the company's continued lack of profitability (GlobeNewswire)
Adjusted operating expenses increased to $145.2 million in Q2 2025, up 16% year-over-year, reflecting sustained high investment levels that may weigh on short-term margins (GlobeNewswire)
Beginning January 1, 2025, CMS reduced the Medicare Physician Fee Schedule rate for CPT code 93229 (mobile cardiac telemetry), potentially lowering reimbursement for Zio AT services and negatively affecting revenue (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

iRhythm Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

iRhythm Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IRTC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs